These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36269298)

  • 1. Sub-erythrodermic psoriasis successfully treated with bimekizumab: A case report.
    Valenti M; Gargiulo L; Ibba L; Pavia G; Narcisi A; Costanzo A
    Dermatol Ther; 2022 Dec; 35(12):e15952. PubMed ID: 36269298
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab.
    Megna M; Battista T; Potestio L; Ruggiero A; Ventura V; Fabbrocini G; Picone V
    J Cosmet Dermatol; 2023 Mar; 22(3):1146-1148. PubMed ID: 36448190
    [No Abstract]   [Full Text] [Related]  

  • 3. Two cases of generalized pustular psoriasis successfully treated with bimekizumab.
    Hagino T; Saeki H; Kanda N
    J Dermatol; 2023 Oct; 50(10):e357-e358. PubMed ID: 37334759
    [No Abstract]   [Full Text] [Related]  

  • 4. Recurrent erythrodermic psoriasis and polycythemia successfully treated with brodalumab.
    Bernardini N; Skroza N; Tolino E; Mambrin A; Balduzzi V; Marchesiello A; Michelini S; Volpe S; Maddalena P; Proietti I; Potenza C
    Dermatol Ther; 2020 Nov; 33(6):e14338. PubMed ID: 32975343
    [No Abstract]   [Full Text] [Related]  

  • 5. A case of erythrodermic psoriasis successfully treated with guselkumab.
    Megna M; Ruggiero A; Camela E; Fabbrocini G; Marasca C
    Dermatol Ther; 2020 Mar; 33(2):e13238. PubMed ID: 31997488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.
    Koutsoukou XA; Papadavid E; Theodoropoulos K; Rigopoulos D
    Dermatol Ther; 2014; 27(5):257-9. PubMed ID: 24813816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythrodermic psoriasis successfully and rapidly treated with brodalumab: Report of two cases.
    Megna M; Fabbrocini G; Ferrillo M; Cinelli E
    Dermatol Ther; 2020 Nov; 33(6):e14351. PubMed ID: 32981222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bimekizumab for Moderate-to-Severe Plaque Psoriasis.
    Gotesman RD; Vender R
    Skin Therapy Lett; 2021 May; 26(3):1-4. PubMed ID: 34077151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With Psoriasis.
    Bagel J; Tatla D; Hellot S; Knapp B; Murphy C; Peterson L; Sebastian M
    J Drugs Dermatol; 2022 Feb; 21(2):162-171. PubMed ID: 35133113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
    Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
    J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?
    Megna M; Potestio L; Fabbrocini G; Cinelli E
    Dermatol Ther; 2021 Sep; 34(5):e15030. PubMed ID: 34137492
    [No Abstract]   [Full Text] [Related]  

  • 12. Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab.
    Pizzatti L; Mugheddu C; Sanna S; Atzori L; Rongioletti F
    Dermatol Ther; 2020 May; 33(3):e13348. PubMed ID: 32239791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bimekizumab for psoriasis.
    Rodrigues MA; Freitas E; Torres T
    Drugs Today (Barc); 2022 Jun; 58(6):273-282. PubMed ID: 35670705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bimekizumab versus Secukinumab in Plaque Psoriasis.
    Reich K; Warren RB; Lebwohl M; Gooderham M; Strober B; Langley RG; Paul C; De Cuyper D; Vanvoorden V; Madden C; Cioffi C; Peterson L; Blauvelt A
    N Engl J Med; 2021 Jul; 385(2):142-152. PubMed ID: 33891380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
    Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A
    Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythrodermic psoriasis.
    Mumoli N; Vitale J; Gambaccini L; Sabatini S; Brondi B; Cei M
    QJM; 2014 Apr; 107(4):315. PubMed ID: 23764512
    [No Abstract]   [Full Text] [Related]  

  • 17. Ixekizumab as treatment of erythrodermic psoriasis.
    Trovato E; Orsini C; Russo F; Cortonesi G; Rubegni P
    Dermatol Ther; 2021 Mar; 34(2):e14868. PubMed ID: 33571383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two cases of refractory erythrodermic psoriasis effectively treated with secukinumab and a review of the literature.
    Liu LC; Jin XH; Sun C; Xia JX
    Dermatol Ther; 2021 Mar; 34(2):e14825. PubMed ID: 33527631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythrodermic psoriasis improved by panitumumab, but not bevacizumab.
    Nishizawa A; Satoh T; Yokozeki H
    Acta Derm Venereol; 2012 Jul; 92(4):360-1. PubMed ID: 22565356
    [No Abstract]   [Full Text] [Related]  

  • 20. Bimekizumab for the Treatment of Psoriasis.
    Freitas E; Blauvelt A; Torres T
    Drugs; 2021 Oct; 81(15):1751-1762. PubMed ID: 34623614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.